^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FCGR2B I232T

    i
    Other names: FCGR2B, Fc Fragment Of IgG Receptor IIb, Low Affinity Immunoglobulin Gamma Fc Region Receptor II-B, Fc Fragment Of IgG Low Affinity IIb Receptor For (CD32), Fc Fragment Of IgG Low Affinity IIb Receptor (CD32), Fc Gamma Receptor IIb, IgG Fc Receptor II-B, Fc-Gamma RII-B, Fc-Gamma-RIIb, FcRII-B, CDw32, IGFR2, FCG2, CD32, Low Affinity Immunoglobulin Gamma Fc Region Receptor II-C, Fc Fragment Of IgG Low Affinity II Receptor For (CD32), IgG Fc Receptor II-C, Fc-Gamma RII-C, Fc Gamma RIIb, Fc-Gamma-RI
    Entrez ID:
    2213
    Related biomarkers:
    Expression
    Associations

    News

    Trials
    over4years
    Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. (PubMed, Blood Adv)
    FCGR2B was associated with poorer PFS in multivariate analyses comparing T232T with I232I in rituximab- but not obinutuzumab-treated patients with DLBCL (HR, 4.40; 95% CI, 1.71-11.32; P = .002; multiple-test-adjusted P = .03); however, this genotype was rare (n = 13). This study shows that FcγR genotype is not associated with response to rituximab/obinutuzumab plus chemotherapy in treatment-naive patients with advanced FL or DLBCL.
    Clinical • Journal
    |
    FCGR2A (Fc fragment of IgG receptor IIa) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • FCGR2B (Fc Fragment Of IgG Receptor IIb)
    |
    FCGR2A R131H • FCGR2B I232T
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab)